
Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth.
Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely successful launch last year, plunged 72% year-on-year to £188 million, hit by fewer of the shots being given out in the US.